Management of amiodarone-induced thyrotoxicosis.
Thyrotoxicosis occurs in up to 3% of people prescribed amiodarone in the UK. The management of amiodarone-induced thyrotoxicosis remains a clinical challenge, as data on optimal treatment from controlled trials are not available. This review will focus on current lines of management.
D000638:Amiodarone / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D006801:Humans; D013971:Thyrotoxicosis / Q000139:chemically induced* / Q000628:therapy
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone